Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-RAPID: Certolizumab Pegol in Japanese RA Patients
NCT00791999Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2008
- Primary completion
- Jan 2010
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Nov 2008; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00791999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791999.